Sangamo Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and a Favorable Safety Profile

Click here to view

Presentation

Poster: Optimal Drug Product Presentation and Container Closure Selection for AAV-Based Genomic Medicines

Download PDF